Moderna (MRNA)
(Real Time Quote from BATS)
$57.44 USD
+0.13 (0.23%)
Updated Oct 16, 2024 03:53 PM ET
After-Market: $57.45 +0.01 (0.02%) 4:16 PM ET
4-Sell of 5 4
F Value B Growth D Momentum F VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$57.44 USD
+0.13 (0.23%)
Updated Oct 16, 2024 03:53 PM ET
After-Market: $57.45 +0.01 (0.02%) 4:16 PM ET
4-Sell of 5 4
F Value B Growth D Momentum F VGM
Zacks News
1-Year Tour From Market Crash to Boom: 5 Top ETFs
by Sweta Killa
The stock market staged a strong rebound from the lows and is currently hitting new highs with the major bourses crossing new milestones.
Moderna (MRNA) Begins Pediatric Study on COVID-19 Vaccine
by Zacks Equity Research
Moderna is developing its COVID-19 vaccine, mRNA-1273, for different patient populations. It is also developing booster vaccine candidates as well as a next-generation COVID vaccine.
Company News for Mar 17, 2021
by Zacks Equity Research
Companies in the news are: JBL, CNF, OPRX, MRNA
Lilly (LLY) Mirikizumab Meets Ulcerative Colitis Study Goal
by Zacks Equity Research
Lilly's (LLY) mirikizumab meets primary endpoint and key secondary endpoints in phase III ulcerative colitis study.
AstraZeneca (AZN) COVID-19 Shot Faces Doubts Over Blood Clots
by Zacks Equity Research
The EMA will continue to investigate whether AstraZeneca's (AZN) COVID-19 vaccine was the cause of the blood clot events or if these were due to other reasons.
Gilead (GILD), Merck Collaborate for Long-Acting HIV Treatments
by Zacks Equity Research
Gilead (GILD) collaborates with Merck for developing long-acting treatments for HIV patients.
J&J (JNJ) Outperforms the Industry Year to Date: Here's Why
by Zacks Equity Research
J&J's (JNJ) shares are up this year mainly due to successful development of its COVID-19 vaccine.
Regeneron (REGN), Sanofi's Libtayo Positive for Cervical Cancer
by Zacks Equity Research
Regeneron (REGN) and partner Sanofi announce favorable data on their oncology drug Libtayo from a phase III study on cervical cancer.
Air Travel Demand Nears 1-Year High: ETFs to Fly High
by Sweta Killa
According to the latest data from Transportation Security Administration (TSA), about 1.357 million travelers checked in at American airports on Mar 12 - the highest number since Mar 15, 2020.
Sanofi (SNY)/Translate Bio COVID-19 Vaccine in Clinical Stage
by Zacks Equity Research
The phase I/II clinical study on Sanofi (SNY)/Translate Bio's (TBIO) COVID-19 vaccine candidate will assess its safety, immune response and reactogenicity.
Novavax's (NVAX) COVID-19 Vaccine Shows Final Efficacy of 96.4%
by Zacks Equity Research
Novavax's (NVAX) COVID-19 vaccine candidate, NVX-CoV2373, proves to be 96.4% effective in final analysis in the phase III study in the United Kingdom. Shares up.
AstraZeneca (AZN) Defends COVID-19 Vaccine Safety With Data
by Zacks Equity Research
AstraZeneca (AZN) announces analysis of safety data of more than 17 million people vaccinated with its vaccine, demonstrating no increased risk of blood clot.
Stock Market News for Mar 12, 2021
by Zacks Equity Research
Benchmarks closed in the positive territory on Thursday after President Biden signed a $1.9 trillion stimulus package to boost the coronavirus pandemic plagued economy, while tech shares also made a comeback
J&J (JNJ) COVID-19 Vaccine Gets Conditional Approval in Europe
by Zacks Equity Research
J&J's (JNJ) single-shot COVID-19 vaccine set to be available in Europe from April.
Vertex (VRTX) Type I Diabetes Candidate Clinical Study Begins
by Zacks Equity Research
Vertex (VRTX) begins early-stage clinical study on cellular therapy, VX-880 for type-I diabetes. FDA also grants Fast Track status to the candidate.
Dow Hits New All-Time High Close as Rescue Bill Passes
by Mark Vickery
Expectations are now for a full-throated economic recovery to take hold, which happens to be dovetailing with the reopening of around a dozen states.
BioDelivery (BDSI) Beats Q4 Earnings Estimates, Stock Up
by Zacks Equity Research
BioDelivery's (BDSI) strong Belubca sales drive the top line. Symproic further boosts revenues. The company expects total revenues to be in the range of $170 - $180 million in 2021.
VBI Vaccines (VBIV) Up on Monovalent COVID-19 Vaccine Study
by Zacks Equity Research
VBI Vaccines (VBIV) is developing a monovalent and trivalent COVID-19 vaccines in separate phase I/II studies.
Is Moderna (MRNA) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Is (MRNA) Outperforming Other Medical Stocks This Year?
5 Beaten-Down Stocks of Nasdaq ETF With Upside Potential
by Sweta Killa
We highlighted five stocks from the ETF that were hit badly in the tech rout but might reverse the trend, given their solid Zacks Rank #1 (Strong Buy) or 2 (Buy) and positive earnings estimate revisions in a month.
Pfizer's (PFE) Vaccine Seems Potent Against COVID-19 Strains
by Zacks Equity Research
Pfizer's (PFE) coronavirus vaccine seems to neutralize the more contagious variants of the original coronavirus in laboratory studies.
Pfizer/Valneva Lyme Disease Vaccine Candidate Enters Phase II
by Zacks Equity Research
Pfizer (PFE) and Valneva are jointly developing a vaccine candidate for Lyme disease. It is the only candidate in clinical development.
IBM & Moderna Partner to Augment COVID-19 Vaccine Management
by Zacks Equity Research
IBM and Moderna (MRNA) team up to explore utility of hybrid cloud and blockchain technology to enhance COVID-19 vaccine management and stem the spread of the contagion.
Vaccine Miracles: Does JNJ Kill the Profit Path for MRNA and NVAX?
by Kevin Cook
New vaccine entrant gets approval before Novavax, while herd immunity ideas put sales in doubt.
USANA Health (USNA) Soars to 52-Week High, Time to Cash Out?
by Zacks Equity Research
USANA Health (USNA) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.